Please assess the completion status of the following clinical trial:

Trial Title: Vascular Function, Endothelin, and Inflammation in Pre-diabetic Obesity Versus Lean Healthy Controls

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* healthy~* normotensive (BP\<140/95 mmHg)~* lean and obese~* 18 and 55 years~* women must be premenopausal~Exclusion Criteria:~* use of pharmacologic agents or recreational drugs, with the exception of occasional use of non-narcotic pain medications~* blood pressure (\>140/90 mmHg)~* elevated cholesterol (LDL \>130 mg/dL)~* diabetes mellitus (by ADA criteria)~* evidence of coronary and/or peripheral vascular disease by history and physical exam~* \>5 kg change in weight in the preceding 3 months~* chronic systemic illness with recognized metabolic effects~* hepatitis C and HIV~* recognized systemic inflammatory or autoimmune processes such as rheumatoid arthritis or systemic lupus erythematosis~* Raynaud's phenomenon or other abnormalities of hand or finger perfusion~* regular participation in endurance or high-performance athletic activity~* history of aspirin or salsalate sensitivity including aspirin-induced asthma~* prior treatment with salsalate, pentoxyfilline, or monoclonal anti-TNFalpha antibodies~* pregnancy~* liver transaminase levels \>3 times the upper limit of normal~* creatinine \>1.5 mg/dL~* history of a cellular immunodeficiency-related opportunistic infections, such as an endemic mycosis (eg. histoplasmosis) or mycobacterial infection (eg tuberculosis)~* reactive tuberculin skin test~* history of malignancy except for basal cell carcinoma of the skin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Acute Salsalate (Type: EXPERIMENTAL): Nondiabetic lean and obese subjects will be studied in this arm. Subjects will be studied at baseline and after a single dose of oral salsalate.
- Chronic Salsalate - Obese (Type: EXPERIMENTAL): Obese subjects will be studied in this arm. Subjects will be studied at baseline and after 2 months' treatment with oral salsalate.
- Chronic Salsalate - Lean (Type: EXPERIMENTAL): Lean subjects will be studied in this arm. Subjects will be studied at baseline and after 2 months' treatment with oral salsalate. The effects of an acute fatty acid infusion on vascular function will be measured on both occasions.

Based on this trial design, predict the completion outcome and termination type (if applicable).